Comparison of Clinical Efficacy of Submucosal Dexamethasone and Oral Trypsin-chymotrypsin for Reduction of Postoperative Sequelae After Lower Third Molar Surgery

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorB.P. Koirala Institute of Health Sciences

About this trial

Pain, edema and trismus are the most frequent postoperative sequelae to surgical removal of impacted teeth, all of are due to the local inflammatory response.

Use of corticosteroids decrease tissue mediators of inflammation and reduce edema.

Use of trypsin-chymotrypsin elaborates the enzymes esterase in blood plasma that inhibits inflammation by hydrolytic degradation of the inflammatory peptides.

Eligibility criteria

Qualifiers

Clinically healthy patients (ASA I) patient free of any systemic diseases that could interfere with wound healing or surgical operation.

Free of any recent anti-inflammatory drug intake or being under long term treatment with medicaments that will obscure the assessment of the inflammatory response as NSAIDs, steroids, or antihistamines

Free from allergy to the drugs used in the study

Patients requiring surgical removal of the mandibular impacted third molar

Disqualifiers

Patients who are ASA II to ASA VI.

Patients already on corticosteroids through any route.

Patients with known allergy to any drugs.

Pregnant and lactating females

Trial design

Treatments tested in this trial

  • Dexamethasone
  • Chymotrypsin

Treatment groups

50 Participants
are divided into 2 treatment groups